Navigation Links
SZX12 Research Stereo Microscope

ProductsSZX12 Research Stereo Microscope
Company Olympus America Scientific
Item SZX12 Research Stereo Microscope
Features 
  • The 0.5x and 1.6x objectives and 10x eyepieces on the SZX12 gives an effective zoom range of 3.5x to 144x, or a 41:1 ratio.
  • 2.5x Auxiliary Lens - The SZX-AL20X lens attaches to the 1.0x objective, increasing total magnification by 2.5x while increasing resolution to 800 lines/mm. This high magnification and resolution closely match the view seen by a 20x objective on a compound microscope.
  • Three transmitted light bases-basic, advanced and darkfield versions.
  • The coaxial illuminator has a 1.5x magnification factor and a quarter wave plate to reduce glare. It is powered by a fiber optic illuminator.
  • Stereo fluorescence is easily accomplished by a 100W mercury lamp and a choice of two fluorescence illuminators: the standard model (SZX-RFL2) employs a variety of filter sets illuminating the specimen through the objective in the traditional manner of a fluorescence microscope; the advanced model (SZX-RFL3) also employs a variety of filter sets but illuminates the specimen from outside the objective, eliminating auto-fluorescence from the lens system.
Description The SZX microscope system is the ultimate research stereo microscope in the Olympus line. Long working distance, wide zoom range, excellent image clarity and easy operation are matched by a modular system of mechanical and motorized components giving the SZX great flexibility, allowing adaptation to meet the needs of virtually any stereo microscope user
Info Olympus America Scientific
Customer Service: (800) 645-8160
Web site: http://www.olympusamerica.com

Related medicine products :

1. Qflow 400 (Research Model)
2. IX71 Inverted Research Microscope
3. IX81 Inverted Motorized Research Microscope
4. The Clinical Reference Laboratories at National Jewish Medical and Research Center
5. Eppendorf Research Series 2100 Adjustable-volume Pipette
6. Eppendorf Research Series 2100 Adjustable-volume Pipette, 20-200 l
7. Eppendorf Research Series 2100 Adjustable-volume Pipette, 2.0-20 l
8. Eppendorf Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl
9. Eppendorf Research Series 2100 Adjustable-volume Pipette, 10-100 l
10. Eppendorf Research pro Electronic Pipette, 50-1,000 uL, single channel with charging adaptor
11. Research pro
The Coreograft PLIF Allograft System is a wedge shaped, cortical strut designed to provide anterior column support and facilitate interbody fusion. This system includes a specially designed instrumen
Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts
VG2 PLIF Allograft is comprised of two cortical planks of bone surrounding a cancellous center. The cortical planks provide strength for anterior column support. The cancellous bone provides a lattic
Ramp allograft is machined from cortical bone to combine column support. The graft is machined with a textured surface for increased stability and resistance to graft migration. This allograft can be
Medicine Products:
(Date:7/25/2008)...troviral therapy may be due to genetic factors , ...ew study challenges the long-held belief that the ...s ability to restore itself after HIV patients are... (HAART). , From 50 percent to 90 percent of HI...Intravenous drug use is the main cause of both typ...
(Date:7/25/2008)...eaconEquity.com announces the,availability of Trad...can view all of the daily trading notes for free b...Trade Alerts include: DUSA Pharmaceuticals Inc. (N...Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), Adol...: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., Join...
(Date:7/25/2008)...ficant Improvements in Members, Health, ATLANTA, ...in health,care quality management solutions for he...ntered into a long-term agreement with Wellmark, I...n on Quality(SM) Incent and,Reward Best Practices ...rimary care clinicians to promote improved quality...
(Date:7/25/2008)...wire/ -- AutoGenomics, Inc. today,announced that i...ith the,Securities and Exchange Commission relatin...s of its common stock. The number of shares of com... to be offered by,AutoGenomics, Inc., and the pric...ined., J.P. Morgan Securities Inc. is acting as s...
Breaking Medicine News(10 mins):Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...thod of treating childhood brain tumours, aimed at...to be trialled at hospitals around the US. Researc...blastoma – the most common malignant childhood bra...ower radiation and increased chemotherapy doses th...
...only used in vitro fertilisation (IVF) technique i...e the risk of babies being born with abnormalities... Pasteur Institute in Paris, France, say that men ...ther, more serious genetic faults that can be pass...
...g to a new study infants born during the night hav...h than those born during the day. There is also a ... which may be partly explained by hospital staff s...ours between 5pm and 1am are high risk periods for...
...ng drugs via nasal spray might overcome a major ob...according to researchers.Based on early studies in...er's Research Center in St. Paul, Minnesota, repor...nā€ could breach the blood-brain barrier, which pro...
Other Medicine News:Health News:Nasal Spray Could Take Drugs Directly to Brain 2
(Date:7/24/2008)...RLEANS, July 24 /PRNewswire-USNewswire/ -- There a...mental illnesses, according to a new,report releas...e,devastating effects that mental illnesses have o...e, mental illness affects nearly 60 million Americ... Research and Manufacturers,of America (PhRMA), fe...
(Date:7/24/2008)...ORK, July 24 /- MacroChem C...ced results of a Phase 2 clinical trial,involving ...nter,open-label efficacy and safety study of EcoN...t of onychomycosis (nail fungus). The composite,pr... cure" defined as,negative mycology (negative fung...
(Date:7/23/2008)...LE, July 23 /- Sound Pharmaceuticals ...ation with the FDA for the clinical,testing of a p...on of,chemotherapy induced hearing loss or ototoxi...5, will be tested in advanced stage lung cancer,an... based chemotherapy.,This marks the second develop...
(Date:7/23/2008)...RANCISCO, July 23 /- InCode BioPharma...ny, today announced preclinical test,results demon...rC3-1 for,the treatment of the rare chronic blood .... The complete results will be presented at the XX...tzerland, September 28,2008., The only treatment...
Breaking Medicine Technology:More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Schering Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter Full Year Financial Result 2393 1Schering Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter Full Year Financial Result 2393 2FOXO factor promotes survival of oxygen deprived cancer cells 8854 1FOXO factor promotes survival of oxygen deprived cancer cells 8854 2New research tools are too complex for easy answers researchers say 8852 1New research tools are too complex for easy answers researchers say 8852 2New research tools are too complex for easy answers researchers say 8852 3Copy number variation may stem from replication misstep 1735 1Copy number variation may stem from replication misstep 1735 2Copy number variation may stem from replication misstep 1735 3
...esented at Society of Nuclear,Medicine Annual Meet...Call/ --,Immunomedics, Inc. , a biopharmaceutical ...s to treat cancer and other serious,diseases, toda...,(CEA) antibody, labetuzumab, labeled with the rad...tive when given in two doses,to patients with colo...
... /PRNewswire/ -- , - Cipralex Better Tolerated and... Lundbeck A/S announces new study data published t...pinion, demonstrating that,Cipralex(R) (escitalopr...ent of patients with major depressive disorder (MD...eatment(1). The study,directly compared Cipralex(R...
Other Medicine Technology:Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 2Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 3Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 4Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 5